Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 59 Leukemia 13 Precursor Cell Lymphoblastic Leukemia-Lymphoma 12 Gastrointestinal Stromal Tumors 12 Leukemia, Myeloid, Chronic-Phase 11 Neoplasms 5 Blast Crisis 4 Recurrence 3 Bronchiolitis Obliterans Syndrome 3 Synovitis, Pigmented Villonodular 2 Philadelphia Chromosome 2 Neoplasm Metastasis 2 Melanoma 2 Leukemia, Myeloid, Accelerated Phase 2 Leukemia, Myeloid 2 Hematologic Diseases 2 Bone Marrow Diseases 2 Sarcoma 1 Piebaldism 1 Peritoneal Neoplasms 1 Ovarian Neoplasms 1 Neurofibromatoses 1 Neurofibroma, Plexiform 1 Neurofibroma 1 Neoplastic Processes 1 Myeloproliferative Disorders 1 Mucosal Lentiginous Melanoma 1 Mastocytosis, Systemic 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, Non-Hodgkin 1

Interventions

Imatinib Mesylate 3 Radiotherapy 2 Nivolumab 2 relatlimab 1 palbociclib 1 nilotinib 1 Surveys and Questionnaires 1 Radiotherapy, Intensity-Modulated 1 Radiosurgery 1 Radiation 1 Proton Therapy 1 Photochemotherapy 1 Pemetrexed 1 Immunoglobulin G 1 Disulfides 1 Dihematoporphyrin Ether 1 Dasatinib 1 Cyclophosphamide 1 Blood Specimen Collection 1 Bacterial Load 1 Afatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Chordoma × nilotinib × Clear all

NCT01407198 2025-12-19

Nilotinib With Radiation for High Risk Chordoma

Massachusetts General Hospital

Phase 1 Completed

Chordoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡